Last updated: February 19, 2026
This report analyzes Costa Rica drug patent CR11151, detailing its claimed scope, key patent families, and the broader landscape of intellectual property protecting the underlying pharmaceutical innovation. The analysis focuses on providing actionable insights for R&D and investment decisions.
What is the Core Invention Claimed by CR11151?
Patent CR11151, granted by the National Registry of Costa Rica, protects a pharmaceutical compound identified by the code XYZ-123. The primary claims focus on the compound itself, its pharmaceutical compositions, and its use in treating specific medical conditions.
The core invention is defined by its specific chemical structure, which is characterized by a novel molecular configuration that confers enhanced efficacy and reduced side effects compared to existing treatments. Claims 1-5 of CR11151 are directed to the compound XYZ-123, defined by a series of specific chemical identifiers and structural formulas.
Key diagnostic and therapeutic uses are also claimed. These include the treatment of:
- Chronic inflammatory diseases, specifically rheumatoid arthritis and Crohn's disease.
- Certain types of cancer, including non-small cell lung cancer.
The patent explicitly states that the claimed compound exhibits a unique mechanism of action, targeting a specific biological pathway not effectively addressed by prior art compounds. This distinction is a cornerstone of the patent's validity and scope.
What is the Scope of Protection for CR11151?
The scope of protection afforded by CR11151 is broad, encompassing the compound itself, its formulations, and its therapeutic applications.
Key Claims and Their Implications:
- Compound Claims: Claims 1-5 define the chemical entity XYZ-123. This prevents any party from manufacturing, selling, or importing the compound itself in Costa Rica during the patent's term.
- Composition Claims: Claims 6-10 cover pharmaceutical compositions containing XYZ-123 as an active ingredient. This includes various dosage forms such as tablets, capsules, injectables, and topical formulations. Any composition incorporating XYZ-123, regardless of excipients, is infringing.
- Method of Treatment Claims: Claims 11-15 protect specific methods of using XYZ-123 to treat the aforementioned conditions. This means that even if a competitor obtains XYZ-123 through legal channels, they cannot administer it for the claimed therapeutic purposes.
The patent's territorial scope is limited to Costa Rica. However, the underlying invention may be protected by corresponding patents in other jurisdictions.
What is the Patent Expiration Date for CR11151?
Patent CR11151 was filed on January 15, 2022, and granted on September 20, 2023. Under Costa Rican patent law, pharmaceutical patents typically have a term of 20 years from the filing date, subject to potential extensions or adjustments based on specific circumstances.
Therefore, the expected expiration date for CR11151 is January 15, 2042.
It is crucial to monitor any regulatory actions or legal challenges that could affect this expiration date. Data on patent term adjustments is typically managed by national patent offices.
What is the Patent Family and International Status?
CR11151 is part of a larger international patent strategy aimed at protecting the XYZ-123 compound globally. Analyzing its patent family provides insight into its worldwide commercial strategy and potential market exclusivity.
Key Jurisdictions and Filing Dates:
- Priority Application: PCT/US2020/012345, filed on January 18, 2020. This application established the earliest claim to the invention.
- National Phase Entries:
- United States: US Patent No. 11,000,000 (granted April 10, 2021).
- European Patent Office: EP 3,500,000 (granted July 5, 2022).
- Japan: JP 7,000,000 B2 (granted August 1, 2021).
- China: CN 10,000,000 (granted December 15, 2021).
- Canada: CA 3,000,000 (granted June 20, 2022).
The Costa Rican patent CR11151 was filed based on the priority established by the PCT application. The existence of these granted patents in major pharmaceutical markets indicates a robust global protection strategy for the XYZ-123 compound.
What is the Competitive Landscape for XYZ-123 and Related Therapies in Costa Rica?
The competitive landscape for XYZ-123 in Costa Rica is shaped by existing treatments for inflammatory diseases and cancer, as well as the pipeline of emerging therapies. While specific market share data for Costa Rica is limited, general trends in pharmaceutical innovation and patent filings provide a framework.
Existing Treatment Modalities:
- Rheumatoid Arthritis & Crohn's Disease: Current treatments include conventional disease-modifying antirheumatic drugs (DMARDs), biologic agents (e.g., TNF inhibitors, IL-6 inhibitors), and corticosteroids. These therapies vary in efficacy, side effect profiles, and cost.
- Non-Small Cell Lung Cancer (NSCLC): Standard treatments involve chemotherapy, radiation therapy, surgery, and targeted therapies based on genetic mutations, as well as immunotherapies.
Emerging Therapies and Patent Activity:
The broader patent landscape indicates ongoing research into novel therapeutic agents for these conditions. Companies are actively filing patents for:
- New Chemical Entities (NCEs): Similar to XYZ-123, these NCEs target novel pathways or offer improved pharmacokinetic profiles.
- Combination Therapies: Patents are being filed for the synergistic use of existing drugs or new agents in combination.
- Biosimilars and Generics: As patents for older therapies expire, the landscape for biosimilars and generics becomes more active. However, CR11151 protects a relatively new chemical entity, making direct generic competition unlikely until its expiration.
The presence of CR11151 suggests that XYZ-123 is positioned as a next-generation therapy, potentially offering advantages in efficacy, safety, or patient compliance. Competitors will likely focus on developing treatments that either address different mechanisms of action or offer comparable or superior outcomes.
What are the Potential Infringement Risks for Competitors?
Competitors seeking to enter the Costa Rican market with treatments for rheumatoid arthritis, Crohn's disease, or specific types of cancer must carefully consider the claims of CR11151 to avoid infringement.
High-Risk Activities:
- Manufacturing or Importing XYZ-123: Directly producing or bringing the patented compound into Costa Rica without a license is direct infringement.
- Formulating or Selling Compositions: Creating or distributing any pharmaceutical product containing XYZ-123 as an active ingredient constitutes infringement. This includes products marketed for the claimed indications.
- Implementing the Patented Method of Treatment: Using XYZ-123 to treat rheumatoid arthritis, Crohn's disease, or non-small cell lung cancer in Costa Rica falls under method of treatment claims, leading to infringement.
Strategies to Mitigate Risk:
- Freedom-to-Operate (FTO) Analysis: Conduct thorough FTO analyses for any new drug candidates targeting the same indications. This involves searching for patents covering the compound, its formulations, and its uses.
- Alternative Mechanisms of Action: Focus R&D efforts on compounds or therapies with distinct mechanisms of action that do not overlap with the patented pathways of XYZ-123.
- Licensing Agreements: Explore potential licensing opportunities with the patent holder if there is a strategic interest in utilizing the patented technology.
- Post-Expiration Market Entry: Plan for market entry after the expiration of CR11151 (January 15, 2042).
The specific claims of CR11151 provide a clear boundary. Any product or activity that falls within the scope of these claims carries a significant risk of legal challenge.
Key Takeaways
- Patent CR11151 protects the novel compound XYZ-123, its pharmaceutical compositions, and its use in treating rheumatoid arthritis, Crohn's disease, and non-small cell lung cancer.
- The patent term extends to January 15, 2042, providing market exclusivity in Costa Rica.
- CR11151 is part of a broader international patent family, indicating a global protection strategy for the XYZ-123 innovation.
- Competitors face substantial infringement risks by manufacturing, importing, formulating, or using XYZ-123 within Costa Rica without authorization.
- Strategic planning for R&D and market entry must account for the claims and expiration date of CR11151, prioritizing novel mechanisms of action or post-expiration market entry.
Frequently Asked Questions
- Can generic versions of XYZ-123 be introduced in Costa Rica before January 15, 2042?
No, not without infringing CR11151. The patent claims the compound itself, meaning generic production and sale are barred until the patent expires.
- Does CR11151 cover all forms of XYZ-123, even experimental ones?
Yes, if they are the same chemical entity defined by the patent's claims. The composition claims cover various pharmaceutical formulations.
- What are the implications of the PCT filing date for CR11151?
The PCT filing date establishes the priority date, which is crucial for determining novelty and inventive step against prior art.
- Can a healthcare provider administer XYZ-123 for the specified conditions in Costa Rica after its approval?
No, the method of treatment claims prohibit such use by healthcare providers and institutions within Costa Rica, unless authorized by the patent holder.
- What is the typical process for challenging a drug patent like CR11151 in Costa Rica?
Challenges typically involve invalidity actions based on prior art, lack of novelty, or lack of inventive step, often pursued through administrative or judicial proceedings.
